Risperidone - ValiSeek

Drug Profile

Risperidone - ValiSeek

Alternative Names: Risperidone lipid formulation - ValiSeek; VAL-401

Latest Information Update: 03 Oct 2016

Price : $50

At a glance

  • Originator Tangent Reprofiling
  • Developer Valiseek
  • Class Antineoplastics; Antipsychotics; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 27 Sep 2016 ValiSeek and Ariana agree to co-develop VAL 401 in for Non small cell lung cancer
  • 01 Aug 2016 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Georgia (PO) (NCT02875340)
  • 15 May 2014 Preclinical trials in Non-small cell lung cancer in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top